Ascelia Pharma: Well placed to secure a partner

Research Update

2024-08-19

08:08

Ascelia’s Q2 confirmed a contained OPEX base. With support from the recent SPARKLE success and the ongoing secured part of the rights issue, Ascelia is well placed to secure a partner before approval and the launch. Our Base Case is SEK 12 (Bull SEK 31 and Bear SEK 2.3); the main reason for the revision is a high degree of dilution from the rights issue, and our earlier Base Case was SEK 17 (Bull SEK 45 and Bear SEK 6).

JU

Johan Unnerus

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.